Abivax Leads Biotechnology Stocks in Year-to-Date Performance
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 22 2025
0mins
Should l Buy ABVX?
Source: SeekingAlpha
Healthcare Sector Performance: The S&P healthcare index (XLV) experienced a YTD increase of 12.2% by mid-December 2025, ranking as the sixth-highest performing sector among the S&P 500 indexes.
Top Biotechnology Stocks: ABIVAX Société Anonyme (ABVX) leads the biotechnology sector with an impressive YTD performance of +1,470.22%, followed by Cidara Therapeutics (CDTX) and Celcuity (CELC) with gains of +721.43% and +672.80%, respectively.
Notable Performers: GRAIL (GRAL) ranks fourth with a YTD performance of +410.31% and holds the highest Quant Rating of Strong Buy 4.98, while Cogent Biosciences (COGT) rounds out the top five with +407.05%.
Healthcare ETFs: Various healthcare ETFs, including XLV, VHT, and IHI, are highlighted, along with predictions for sector outperformers and laggards in 2026.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ABVX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ABVX
Wall Street analysts forecast ABVX stock price to rise
8 Analyst Rating
8 Buy
0 Hold
0 Sell
Strong Buy
Current: 115.420
Low
131.00
Averages
150.71
High
175.00
Current: 115.420
Low
131.00
Averages
150.71
High
175.00
About ABVX
Abivax SA is a clinical stage biopharmaceutical company focusing on the discovery, development and commercialization of anti-viral compounds and therapeutic vaccines against severe and life threatening infectious diseases. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The Company's product pipeline comprises ABX 203, which is the therapeutic vaccine candidate obtained from the Centre for Genetic Engineering and Biotechnology, Cuba (CIGB) and is intended for patients with chronic hepatitis B disease; and ABX196, the adjuvant for therapeutic vaccines, among others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Abivax Reports €530.4M Cash Position for 2025
- Cash Position: As of December 31, 2025, Abivax reported cash, cash equivalents, and short-term investments totaling €530.4 million, providing a projected cash runway into Q4 2027 based on current operating assumptions, ensuring financial stability for the company in the coming years.
- R&D Expense Increase: Research and development expenses rose to €177.8 million in 2025, accounting for 70.9% of operating expenses, compared to €146.5 million (79.0% of operating expenses) in 2024, indicating the company's ongoing commitment to drug development and strategic focus.
- Market Reaction: Despite maintaining a 'Strong Buy' rating amid buyout speculation, Abivax's stock price declined after denying acquisition rumors with AstraZeneca, reflecting market attention on the company's fundamentals.
- Analyst Ratings: Seeking Alpha's Quant Rating on Abivax indicates a positive outlook for the company's future, particularly regarding the advancement of Obefazimod, potentially providing further confidence to investors.
See More
Abivax CEO: No Rush for Deals Ahead of Key Trial
- Cautious Financial Outlook: Abivax CEO Marc de Garidel indicated that the company is not rushing into deals ahead of a pivotal Phase 3 trial readout expected in late Q2 2026, suggesting a strategic decision to wait for better terms in potential partnerships.
- Capital Raising Plans: De Garidel revealed that the company is likely to raise several million dollars through a combination of equity and debt after the trial readout, aiming for a capital influx by late June to support its path to profitability.
- Market Rollout Strategy: Following positive trial data, Abivax plans to seek partners for the market launch of obefazimod outside the U.S., demonstrating confidence in the drug's potential and an openness to external collaborations for commercialization.
- Executive Changes: Abivax announced the appointment of Michael Nesrallah as Chief Commercial Officer and Keith Fournier as Senior Vice President of Global Regulatory Affairs, reflecting strategic adjustments in its leadership team to bolster future business initiatives.
See More
Investment Opportunities in Abivax and Nektar Therapeutics
- Potential Blockbuster for Abivax: Abivax is developing obefazimod for chronic inflammatory diseases, currently in phase 3 trials for ulcerative colitis, with top-line data expected in Q2; if successful, it could lead to regulatory approval and tap into a market projected to reach $14.3 billion by 2035.
- Acquisition Rumors Boost Stock: Despite a 10% decline this year, Abivax's stock has surged over 1,900% in the past year, driven by strong clinical results and acquisition rumors from Eli Lilly and AstraZeneca, suggesting that a buyout could occur at a premium to current prices.
- Strong Cash Position: As of Q3 2025, Abivax reported €589.7 million (approximately $697 million) in cash, sufficient to fund operations into Q4 2027, indicating robust financial health.
- Nektar's Promising Therapy: Nektar's rezpegaldesleukin showed over 80% of patients achieving at least 75% skin improvement in a phase 2b trial for moderate-to-severe atopic dermatitis, positioning it as a strong competitor in the eczema market against established therapies like Dupixent.
See More
Abivax Viewed as a Potential Acquisition Target
- Drug Development Outlook: Abivax's lead drug candidate, obefazimod, is undergoing a phase 3 trial for moderately to severely active ulcerative colitis, with top-line data expected in Q2; if successful, it could lead to the company's first approved therapy, tapping into a market projected to reach $14.3 billion by 2035.
- Strong Financial Position: As of Q3 2025, Abivax reported €589.7 million (approximately $697 million) in cash and cash equivalents, sufficient to fund operations into Q4 2027, indicating robust financial health during its clinical stage.
- Market Competitiveness: Despite a 10% decline in Abivax's stock this year, it has surged over 1,900% in the past year, primarily driven by positive clinical trial results and acquisition rumors from pharma giants Eli Lilly and AstraZeneca, reflecting high market expectations for its future.
- Nektar's Growth Potential: Nektar Therapeutics' rezpegaldesleukin showed promising results in its phase 2b trial for moderate-to-severe atopic dermatitis, with over 80% of patients achieving at least 75% skin improvement at 36 weeks, positioning it as a strong competitor and potential acquisition target for larger pharmaceutical companies.
See More
Abivax Shares Rise After Denying AstraZeneca Acquisition Report
- Stock Movement: Abivax shares rose 2.5% after denying a report about granting AstraZeneca exclusive access to information, with an intraday peak of 18%, reflecting positive market sentiment towards the company's outlook.
- Acquisition Rumors: The company issued an email statement to Bloomberg denying La Lettre's report of any acquisition agreement with AstraZeneca, reinforcing investor confidence in its independence and strategic direction.
- Performance Surge: Over the past year, Abivax's stock has skyrocketed more than 1,700%, driven by acquisition rumors and promising late-stage trial data for its lead asset, obefazimod, targeting ulcerative colitis, indicating strong market interest in its therapeutic potential.
- Market Analysis: Analysts recommend that investors focus on Abivax's fundamentals rather than just the rumors, highlighting its potential in ulcerative colitis treatment, which may attract more long-term investors looking for growth opportunities.
See More
AstraZeneca Poised to Acquire Abivax Amid Surge in Valuation
- Acquisition Potential: AstraZeneca is poised to acquire French biotech Abivax, which saw its market value soar to approximately €7.7 billion ($8.9 billion) in 2025 due to strong clinical progress of its lead drug candidate, positioning AstraZeneca as a key player in the pharmaceutical industry's search for innovative therapies.
- Exclusive Data Access: Since early February, AstraZeneca has held exclusive access to Abivax's data room, with the exclusivity period running until March 23, allowing AstraZeneca time to evaluate the data and potentially formalize an acquisition offer; failure to submit a bid by the deadline could reopen negotiations with other interested parties.
- Attractive Drug Candidate: Abivax's drug candidate obefazimod achieved significant breakthroughs in its Phase 3 clinical trials in July 2025, demonstrating impressive efficacy for patients with moderately to severely active ulcerative colitis, with potential commercialization expected around 2027, and the U.S. market anticipated to represent nearly 70% of its commercial opportunity.
- Political and Strategic Edge: As a European company, AstraZeneca may face less political resistance in acquiring Abivax, particularly given the established relationship between its CEO and Abivax's CEO, which could provide strategic advantages during the approval process, especially under the scrutiny of French regulatory authorities.
See More
Abivax Reports €530.4M Cash Position for 2025
- Cash Position: As of December 31, 2025, Abivax reported cash, cash equivalents, and short-term investments totaling €530.4 million, providing a projected cash runway into Q4 2027 based on current operating assumptions, ensuring financial stability for the company in the coming years.
- R&D Expense Increase: Research and development expenses rose to €177.8 million in 2025, accounting for 70.9% of operating expenses, compared to €146.5 million (79.0% of operating expenses) in 2024, indicating the company's ongoing commitment to drug development and strategic focus.
- Market Reaction: Despite maintaining a 'Strong Buy' rating amid buyout speculation, Abivax's stock price declined after denying acquisition rumors with AstraZeneca, reflecting market attention on the company's fundamentals.
- Analyst Ratings: Seeking Alpha's Quant Rating on Abivax indicates a positive outlook for the company's future, particularly regarding the advancement of Obefazimod, potentially providing further confidence to investors.
See More
Abivax CEO: No Rush for Deals Ahead of Key Trial
- Cautious Financial Outlook: Abivax CEO Marc de Garidel indicated that the company is not rushing into deals ahead of a pivotal Phase 3 trial readout expected in late Q2 2026, suggesting a strategic decision to wait for better terms in potential partnerships.
- Capital Raising Plans: De Garidel revealed that the company is likely to raise several million dollars through a combination of equity and debt after the trial readout, aiming for a capital influx by late June to support its path to profitability.
- Market Rollout Strategy: Following positive trial data, Abivax plans to seek partners for the market launch of obefazimod outside the U.S., demonstrating confidence in the drug's potential and an openness to external collaborations for commercialization.
- Executive Changes: Abivax announced the appointment of Michael Nesrallah as Chief Commercial Officer and Keith Fournier as Senior Vice President of Global Regulatory Affairs, reflecting strategic adjustments in its leadership team to bolster future business initiatives.
See More
Investment Opportunities in Abivax and Nektar Therapeutics
- Potential Blockbuster for Abivax: Abivax is developing obefazimod for chronic inflammatory diseases, currently in phase 3 trials for ulcerative colitis, with top-line data expected in Q2; if successful, it could lead to regulatory approval and tap into a market projected to reach $14.3 billion by 2035.
- Acquisition Rumors Boost Stock: Despite a 10% decline this year, Abivax's stock has surged over 1,900% in the past year, driven by strong clinical results and acquisition rumors from Eli Lilly and AstraZeneca, suggesting that a buyout could occur at a premium to current prices.
- Strong Cash Position: As of Q3 2025, Abivax reported €589.7 million (approximately $697 million) in cash, sufficient to fund operations into Q4 2027, indicating robust financial health.
- Nektar's Promising Therapy: Nektar's rezpegaldesleukin showed over 80% of patients achieving at least 75% skin improvement in a phase 2b trial for moderate-to-severe atopic dermatitis, positioning it as a strong competitor in the eczema market against established therapies like Dupixent.
See More
Abivax Viewed as a Potential Acquisition Target
- Drug Development Outlook: Abivax's lead drug candidate, obefazimod, is undergoing a phase 3 trial for moderately to severely active ulcerative colitis, with top-line data expected in Q2; if successful, it could lead to the company's first approved therapy, tapping into a market projected to reach $14.3 billion by 2035.
- Strong Financial Position: As of Q3 2025, Abivax reported €589.7 million (approximately $697 million) in cash and cash equivalents, sufficient to fund operations into Q4 2027, indicating robust financial health during its clinical stage.
- Market Competitiveness: Despite a 10% decline in Abivax's stock this year, it has surged over 1,900% in the past year, primarily driven by positive clinical trial results and acquisition rumors from pharma giants Eli Lilly and AstraZeneca, reflecting high market expectations for its future.
- Nektar's Growth Potential: Nektar Therapeutics' rezpegaldesleukin showed promising results in its phase 2b trial for moderate-to-severe atopic dermatitis, with over 80% of patients achieving at least 75% skin improvement at 36 weeks, positioning it as a strong competitor and potential acquisition target for larger pharmaceutical companies.
See More
Abivax Shares Rise After Denying AstraZeneca Acquisition Report
- Stock Movement: Abivax shares rose 2.5% after denying a report about granting AstraZeneca exclusive access to information, with an intraday peak of 18%, reflecting positive market sentiment towards the company's outlook.
- Acquisition Rumors: The company issued an email statement to Bloomberg denying La Lettre's report of any acquisition agreement with AstraZeneca, reinforcing investor confidence in its independence and strategic direction.
- Performance Surge: Over the past year, Abivax's stock has skyrocketed more than 1,700%, driven by acquisition rumors and promising late-stage trial data for its lead asset, obefazimod, targeting ulcerative colitis, indicating strong market interest in its therapeutic potential.
- Market Analysis: Analysts recommend that investors focus on Abivax's fundamentals rather than just the rumors, highlighting its potential in ulcerative colitis treatment, which may attract more long-term investors looking for growth opportunities.
See More
AstraZeneca Poised to Acquire Abivax Amid Surge in Valuation
- Acquisition Potential: AstraZeneca is poised to acquire French biotech Abivax, which saw its market value soar to approximately €7.7 billion ($8.9 billion) in 2025 due to strong clinical progress of its lead drug candidate, positioning AstraZeneca as a key player in the pharmaceutical industry's search for innovative therapies.
- Exclusive Data Access: Since early February, AstraZeneca has held exclusive access to Abivax's data room, with the exclusivity period running until March 23, allowing AstraZeneca time to evaluate the data and potentially formalize an acquisition offer; failure to submit a bid by the deadline could reopen negotiations with other interested parties.
- Attractive Drug Candidate: Abivax's drug candidate obefazimod achieved significant breakthroughs in its Phase 3 clinical trials in July 2025, demonstrating impressive efficacy for patients with moderately to severely active ulcerative colitis, with potential commercialization expected around 2027, and the U.S. market anticipated to represent nearly 70% of its commercial opportunity.
- Political and Strategic Edge: As a European company, AstraZeneca may face less political resistance in acquiring Abivax, particularly given the established relationship between its CEO and Abivax's CEO, which could provide strategic advantages during the approval process, especially under the scrutiny of French regulatory authorities.
See More
